Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 26, 2025
Product Development
Axsome’s latest win comes in ADHD, Opthea seeks path after AMD miss, and more: Clinical Report
Plus:
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: New mechanisms in obesity, neurology, ophthalmology
New Year to put new obesity targets to the test, as all eyes on semaglutide in Alzheimer’s and launches in schizophrenia, AMD
BioCentury | Aug 19, 2022
Finance
Carlyle, Abingworth back Opthea’s AMD ambitions in largest-ever Australian deal
First risk-sharing investment since VC’s takeout will position strategic entity Launch to advise Australian biotech as it navigates Phase III with up to $260M
BioCentury | Oct 17, 2020
Finance
Praxis sees strongest first-day among trio of IPOs as NASDAQ nears $16B raised in fresh paper
Among a trio of clinical biotechs pricing IPOs ahead of Friday’s NASDAQ session, demand was highest for Praxis as the company posted a 46% gain, while the reception was more muted for Aligos
BioCentury | Apr 4, 2020
Translation in Brief
HiFiBiO’s platform for antibody screening applied to COVID-19; plus Fundamental’s peptide mimetics for stroke, and BMS-IONpath
BioCentury's roundup of preclinical news
BioCentury | May 14, 2012
Company News
Ark Therapeutics, University College London endocrine/metabolic news
Items per page:
1 - 10 of 15